First Time Loading...

Pharma Foods International Co Ltd
TSE:2929

Watchlist Manager
Pharma Foods International Co Ltd Logo
Pharma Foods International Co Ltd
TSE:2929
Watchlist
Price: 877 JPY 0.57%
Updated: May 20, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

37B
-2%
Assets
Growth Rates:
1 Year
+9%
3 Years
+128%
5 Years
+370%
7 Years
+549%
10 Years
+1 105%
27.8B
-0.6%
Liabilities
Growth Rates:
1 Year
-1%
3 Years
+133%
5 Years
+546%
7 Years
+930%
10 Years
+8 029%
9.2B
-5%
Equity
Growth Rates:
1 Year
+60%
3 Years
+113%
5 Years
+158%
7 Years
+206%
10 Years
+237%

Balance Sheet Decomposition
Pharma Foods International Co Ltd

37B
Assets
27.8B
Liabilities
37B
Assets
27.8B
Liabilities
Current Assets 27.7B
Cash & Short-Term Investments 17B
Receivables 4B
Other Current Assets 6.7B
Non-Current Assets 9.3B
Long-Term Investments 2.7B
PP&E 4.6B
Intangibles 215m
Other Non-Current Assets 1.8B
Current Liabilities 25.8B
Accounts Payable 1B
Accrued Liabilities 80m
Short-Term Debt 17.4B
Other Current Liabilities 7.3B
Non-Current Liabilities 2B
Long-Term Debt 1.5B
Other Non-Current Liabilities 459m

Balance Sheet
Pharma Foods International Co Ltd

Rotate your device to view
Balance Sheet
Currency: JPY
Jul-2014 Jul-2015 Jul-2016 Jul-2017 Jul-2018 Jul-2019 Jul-2020 Jul-2021 Jul-2022 Jul-2023
Assets
Cash & Cash Equivalents
1 514
1 509
2 101
2 861
2 934
4 317
3 283
9 794
8 845
16 306
Cash Equivalents
1 514
1 509
2 101
2 861
2 934
4 317
3 283
9 794
8 845
16 306
Total Receivables
706
674
588
593
880
1 279
2 236
4 917
7 425
4 582
Accounts Receivables
625
551
588
593
880
1 279
2 236
4 917
7 425
4 582
Other Receivables
81
123
0
0
0
0
0
0
0
0
Inventory
204
250
287
604
639
1 065
1 677
2 748
6 066
6 053
Other Current Assets
113
22
183
309
204
228
242
474
1 177
589
Total Current Assets
2 536
2 455
3 160
4 367
4 657
6 888
7 437
17 933
23 513
27 530
PP&E Net
705
717
725
718
734
955
1 769
1 808
4 458
4 404
PP&E Gross
705
717
0
0
0
0
0
0
0
0
Accumulated Depreciation
345
369
0
0
0
0
0
0
0
0
Intangible Assets
2
3
33
44
41
48
45
45
35
41
Goodwill
3
2
1
242
229
191
154
140
270
197
Note Receivable
179
195
163
130
100
78
54
29
0
0
Long-Term Investments
425
254
102
40
139
146
137
335
1 572
2 514
Other Long-Term Assets
84
114
288
303
429
427
501
654
1 311
1 546
Other Assets
3
2
1
242
229
191
154
140
270
197
Total Assets
3 934
N/A
3 739
-5%
4 473
+20%
5 844
+31%
6 328
+8%
8 731
+38%
10 096
+16%
20 944
+107%
31 159
+49%
36 232
+16%
Liabilities
Accounts Payable
136
139
89
139
199
267
450
846
1 176
937
Accrued Liabilities
12
14
1
8
2
2
3
3
70
72
Short-Term Debt
0
0
50
50
50
0
0
2 500
15 400
17 400
Current Portion of Long-Term Debt
1
1
200
454
443
1 067
1 282
945
771
965
Other Current Liabilities
60
111
174
434
732
1 002
1 103
6 684
5 378
5 000
Total Current Liabilities
209
266
515
1 086
1 426
2 338
2 838
10 978
22 795
24 374
Long-Term Debt
1
0
432
1 095
920
2 057
2 322
1 474
718
1 752
Deferred Income Tax
27
16
0
0
0
0
0
0
0
0
Minority Interest
0
0
3
7
17
0
0
0
2
0
Other Liabilities
7
4
29
71
72
21
29
27
572
476
Total Liabilities
243
N/A
286
+18%
979
+242%
2 258
+131%
2 435
+8%
4 415
+81%
5 189
+18%
12 479
+141%
24 087
+93%
26 602
+10%
Equity
Common Stock
2 020
2 031
2 031
2 031
2 031
2 032
2 034
2 038
2 042
2 043
Retained Earnings
323
503
444
346
36
463
1 052
4 600
3 300
5 792
Additional Paid In Capital
1 871
1 882
1 882
1 882
1 883
1 811
1 813
1 817
1 820
1 814
Unrealized Security Profit/Loss
123
42
34
16
12
9
10
8
46
324
Treasury Stock
0
0
0
0
0
0
0
0
138
343
Other Equity
0
0
9
3
3
0
0
2
2
0
Total Equity
3 691
N/A
3 453
-6%
3 494
+1%
3 586
+3%
3 893
+9%
4 316
+11%
4 908
+14%
8 465
+72%
7 072
-16%
9 630
+36%
Total Liabilities & Equity
3 934
N/A
3 739
-5%
4 473
+20%
5 844
+31%
6 328
+8%
8 731
+38%
10 096
+16%
20 944
+107%
31 159
+49%
36 232
+16%
Shares Outstanding
Common Shares Outstanding
29
29
29
29
29
29
29
29
29
29

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.